Physician profile
Minh C DO
NPI 1619964368
$14,525.48
in general payments reported to CMS, 2019-2025
47 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,856 · 2020: $2,186 · 2021: $2,657 · 2022: $1,597 · 2023: $1,834 · 2024: $1,314 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,216 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,216.10 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,037.27 | 2019-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $1,824.30 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Nestle Healthcare Nutrition INC. | $1,367.70 | 2020-2023 | |
| Lilly USA, LLC | $1,186.96 | 2019-2023 | Taltz, Jardiance, Emgality |
| Aimmune Therapeutics, INC. | $815.75 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $799.18 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $577.48 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.18 | 2020-2025 | Jardiance, Synjardy |
| Gilead Sciences, INC. | $541.04 | 2019-2024 | |
| Leo Pharma INC. | $492.76 | 2022-2025 | Adbry |
| Hikma Pharmaceuticals USA | $443.35 | 2019-2021 | |
| Pfizer INC. | $382.53 | 2019-2023 | |
| Amgen INC. | $341.80 | 2019-2025 | Evenity, Tavneos, Otezla |
| Travere Therapeutics, INC. | $328.54 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $273.76 | 2019-2024 | Linzess |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.